Welcome to our dedicated page for P3 Health Partners SEC filings (Ticker: PIIIW), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on P3 Health Partners's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into P3 Health Partners's regulatory disclosures and financial reporting.
P3 Health Partners Inc. Director Thomas Edmunds Price was granted 2,000 restricted stock units (RSUs) on 08/06/2025. Each RSU represents a right to receive one share of Class A common stock and the award vests one year from the grant date, meaning delivery of shares occurs only after vesting. The grant was made under the company’s 2021 Incentive Award Plan and shows an acquisition at no cash price.
After the grant, the filing reports 218,561 shares beneficially owned by the reporting person on a direct basis. This transaction is a typical equity-based compensation award to a director and does not reflect an immediate sale or transfer of issued shares.